Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: A case series

BMC Dermatology

Volumn 7, Issue , 2007, Pages

  Lowes, Michelle A ^a   Chamian, Francesca ^a   Abello, Maria V ^a   Leonardi, Craig ^b   Dummer, Wolfgang ^c   Papp, Kim ^d   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b Central Dermatology   (United States)

^c GENENTECH INC   (United States)

^d PROBITY MEDICAL RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 INTEGRIN; CD11B ANTIGEN; EFALIZUMAB; GLYCOPROTEIN P 15095; INDUCIBLE NITRIC OXIDE SYNTHASE;

ARTICLE; CASE STUDY; CD3+ T LYMPHOCYTE; CELL TRANSPORT; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE PREDISPOSITION; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; PAPULAR RASH; PSORIASIS VULGARIS; SKIN BIOPSY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD11A; ANTIGENS, CD11B; ANTIGENS, CD11C; ANTIGENS, CD3; DENDRITIC CELLS; DRUG ERUPTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOCYTES; NITRIC OXIDE SYNTHASE TYPE II; PSORIASIS; SKIN; T-LYMPHOCYTES;

EID: 36148994531     PISSN: None     EISSN: 14715945     Source Type: Journal    
DOI: 10.1186/1471-5945-7-2     Document Type: Article

References (20)

1. Gottlieb AB Miller B Lowe N Shapiro W Hudson C Bright R Ling M Magee A McCall CO Rist T Dummer W Walicke P Bauer RJ White M Garovoy M Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis J Cutan Med Surg 2003, 7:198-207 12717587
2. Lebwohl M Tyring SK Hamilton TK Toth D Glazer S Tawfik NH Walicke P Dummer W Wang X Garovoy MR Pariser D A novel targeted T-cell modulator, efalizumab, for plaque psoriasis N Engl J Med 2003, 349:2004-2013 10.1056/NEJMoa030002 14627785
3. Dubertret L Sterry W Bos JD Chimenti S Shumack S Larsen CG Shear NH Papp KA CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from a phase III international randomized, placebo-controlled trial Br J Dermatol 2006, 155:170-181 10.1111/j.1365-2133.2006.07344.x 16792770
4. Vugmeyster Y Kikuchi T Lowes MA Chamian F Kagen M Gilleaudeau P Lee E Howell K Bodary S Dummer W Krueger JG Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin Clin Immunol 2004, 113:38-46 10.1016/ j.clim.2004.06.001 15380528
5. Lowes MA Chamian F Abello MV Fuentes-Duculan J Lin SL Nussbaum R Novitskaya I Carbonaro H Cardinale I Kikuchi T Gilleaudeau P Sullivan-Whalen M Wittkowski KM Papp K Garovoy M Dummer W Steinman RM Krueger JG Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a) Proc Natl Acad Sci U S A 2005, 102:19057-19062 1323218 16380428 10.1073/pnas.0509736102
6. Carey W Glazer S Gottlieb AB Lebwohl M Leonardi C Menter A Papp K Rundle AC Toth D Relapse, rebound, and psoriasis adverse events: An advisory group report J Am Acad Dermatol 2006 54 S171 81 10.1016/ j.jaad.2005.10.029 16488339
7. Lowes MA Turton JA Krueger JG Barnetson RS Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: A case series BMC Dermatol 2005, 5:9 1208875 16109173 10.1186/1471-5945-5-9
8. Janeway CA Travers P Walport M Shlomchik M Immunology. The immune sysem in health and disease New York, Garland Publishing 5th 2001
9. Liu YJ Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity Cell 2001 106 259 262 10.1016/ S0092-8674(01)00456-1 11509173
10. MacDonald KP Munster DJ Clark GJ Dzionek A Schmitz J Hart DN Characterization of human blood dendritic cell subsets Blood 2002, 100:4512-4520 10.1182/blood-2001-11-0097 12393628
11. Muller WA Leukocyte-endothelial cell interactions in the inflammatory response Lab Invest 2002, 82:521-533 10.1038/labinvest.3780446 12003992
12. Guerau-de-Arellano M Alroy J Bullard D Huber BT Aggravated Lyme carditis in CD11a-/- and CD11c-/- mice Infect Immun 2005, 73:7637-7643 1273870 16239568 10.1128/IAI.73.11.7637-7643.2005
13. Nicholson GC Tennant RC Carpenter DC Sarau HM Kon OM Barnes PJ Salmon M Vessey RS Tal-Singer R Hansel TT A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: Upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist Pulm Pharmacol Ther 2006 16406722
14. Liberek T Chmielewski M Lichodziejewska-Niemierko M Lewandowski K Rutkowski B Transmigration of blood leukocytes into the peritoneal cavity is related to the upregulation of ICAM-1 (CD54) and Mac-1 (CD11b/ CD18) adhesion molecules Perit Dial Int 2004, 24:139-146 15119634
15. Latger-Cannard V Besson I Doco-Lecompte T Lecompte T A standardized procedure for quantitation of CD11b on polymorphonuclear neutrophil by flow cytometry: Potential application in infectious diseases Clin Lab Haematol 2004, 26:177-186 10.1111/j.1365-2257.2004.00599.x 15163315
16. Maruyama K Ii M Cursiefen C Jackson DG Keino H Tomita M Van Rooijen N Takenaka H D'Amore PA Stein-Streilein J Losordo DW Streilein JW Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages J Clin Invest 2005, 115:2363-2372 1193872 16138190 10.1172/JCI23874
17. Kirby AC Raynes JG Kaye PM CD11b regulates recruitment of alveolar macrophages but not pulmonary dendritic cells after pneumococcal challenge J Infect Dis 2006, 193:205-213 10.1086/498874 16362884
18. Friedl P den Boer AT Gunzer M Tuning immune responses: Diversity and adaptation of the immunological synapse Nat Rev Immunol 2005, 5:532-545 10.1038/nri1647 15999094
19. Lew W Bowcock AM Krueger JG Psoriasis vulgaris: Cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression Trends Immunol 2004, 25:295-305 10.1016/j.it.2004.03.006 15145319
20. Cather JC Menter A Modulating T cell responses for the treatment of psoriasis: A focus on efalizumab Expert Opin Biol Ther 2003, 3:361-370 10.1517/14712598.3.2.361 12662148